Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects

1. Iversen L. Cannabis and the brain. Brain. 2003;126:1252–1270. [PubMed]

2. Pertwee RG. Cannabinoid receptors and pain. Prog. Neurobiol. 2001;63:569–611. [PubMed]

3. Lemberger L. Potential therapeutic usefulness of marijuana. Ann. Rev. Pharmacol. Toxicol. 1980;20:151–172. [PubMed]

4. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry. 2001;178:107–115. [PubMed]

5. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol. 2003;2:291–298. [PubMed]

6. Carlini EA. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon. 2004;44:461–467. [PubMed]

7. Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol. 2005;6:35–42. [PubMed]

8. Cui SS, et al. Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. J. Neurosci. 2001;21:9867–9876. [PubMed]

9. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am. J. Psychiatry. 2004;161:1967–1977. [PubMed]

10. Meyer, J.S., and Quenzer, L.F. 2004. Marijuana and the cannabinoids. In Psychopharmacology: drugs, the brain, and behavior. J.S. Meyer and L.F. Quenzer, editors. Sinauer Associates Inc. Sunderland, Massachusetts, USA. 327–345.

11. Fride, E., and Mechoulam, R. 2003. New advances in the identification and physiological roles of the components of the endogenous cannabinoid system. In Molecular biology of drug addiction. R. Maldonado, editor. Humana Press. Totowa, New Jersey, USA. 173–179.

12. Malberg JE. Implications of adult hippocampal neurogenesis in antidepressant action. J. Psychiatry Neurosci. 2004;29:196–205. [PMC free article] [PubMed]

13. Eisch AJ, Mandyam CD. Drug dependence and addiction, II: adult neurogenesis and drug abuse. Am. J. Psychiatry. 2004;161:426. [PubMed]

14. Cameron HA, McKay RD. Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J. Comp. Neurol. 2001;435:406–417. [PubMed]

15. van Praag H, et al. Functional neurogenesis in the adult hippocampus. Nature. 2002;415:1030–1034. [PubMed]

16. Jiang W, Wang JC, Zhang Z, Sheerin AH, Zhang X. Response of seizure-induced newborn neurons in the dentate gyrus of adult rats to second episode of seizures. Brain Res. 2004;1006:248–252. [PubMed]

17. Shors TJ. Memory traces of trace memories: neurogenesis, synaptogenesis and awareness. Trends Neurosci. 2004;27:250–256. [PMC free article] [PubMed]

18. Santarelli L, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–809. [PubMed]

19. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology. 2004;29:1321–1330. [PubMed]

20. Eisch AJ, Barrot M, Schad CA, Self DW, Nestler EJ. Opiates inhibit neurogenesis in the adult rat hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2000;97:7579–7584. [PMC free article] [PubMed]

21. Nixon K, Crews FT. Binge ethanol exposure decreases neurogenesis in adult rat hippocampus. J. Neurochem. 2002;83:1087–1093. [PubMed]

22. Abrous DN, et al. Nicotine self-administration impairs hippocampal plasticity. J. Neurosci. 2002;22:3656–3662. [PubMed]

23. Yamaguchi M, et al. Repetitive cocaine administration decreases neurogenesis in adult rat hippocampus. Ann. N. Y. Acad. Sci. 2004;1025:351–362. [PubMed]

24. Jin K, et al. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol. Pharmacol. 2004;66:204–208. [PubMed]

25. Rueda D, Navarro B, Martinez-Serrano A, Guzman M, Galve-Roperh I. The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J. Biol. Chem. 2002;277:46645–46650. [PubMed]

26. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83:393–411. [PubMed]

27. Bonhaus DW, Chang LK, Kwan J, Martin GR. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 1998;287:884–888. [PubMed]

28. Howlett AC, et al. Cannabinoid physiology and pharmacology: 30 years of progress [review] Neuropharmacology. 2004;47(Suppl. 1):345–358. [PubMed]

29. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J. Cell. Biochem. 2004;92:949–966. [PubMed]

30. Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. Early determination and long-term persistence of adult-generated new neurons in the hippocampus of mice. Development. 2003;130:391–399. [PubMed]

31. Zhang X, et al. Relations between brain pathology and temporal lobe epilepsy. J. Neurosci. 2002;22:6052–6061. [PubMed]

32. Kempermann G, Jessberger S, Steiner B, Kronenberg G. Milestones of neuronal development in the adult hippocampus. Trends Neurosci. 2004;27:447–452. [PubMed]

33. Watts G. High hopes for cannabinoid analgesia. BMJ. 2004;329:257–258. [PMC free article] [PubMed]

34. Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci. 1999;65:573–595. [PubMed]

35. Tzavara ET, Wade M, Nomikos GG. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J. Neurosci. 2003;23:9374–9384. [PubMed]

36. Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 1998;59:347–352. [PubMed]

37. Welch SP, Dunlow LD, Patrick GS, Razdan RK. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 1995;273:1235–1244. [PubMed]

38. O’Sullivan SE, Kendall DA, Randall MD. Vascular effects of Delta9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. Eur. J. Pharmacol. 2005;507:211–221. [PubMed]

39. Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem. Pharmacol. 2004;68:1691–1698. [PubMed]

40. Biscaia M, et al. Chronic treatment with CP55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology (Berl.). 2003;170:301–308. [PubMed]

41. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. 1997;8:523–532. [PubMed]

42. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002;23:238–245. [PubMed]

43. Gordon JA, Hen R. The serotonergic system and anxiety. Neuromolecular Med. 2004;5:27–40. [PubMed]

44. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther. 1990;253:1002–1009. [PubMed]

45. Arevalo C, de Miguel R, Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav. 2001;70:123–131. [PubMed]

46. Marin S, et al. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol. Biochem. Behav. 2003;74:649–656. [PubMed]

47. Genn RF, Tucci S, Marco EM, Viveros MP, File SE. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol. Biochem. Behav. 2004;77:567–573. [PubMed]

48. Hill MN, Gorzalka BB. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol. 2004;499:291–295. [PubMed]

49. Marco EM, et al. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol. 2004;15:21–27. [PubMed]

50. Shearman LP, et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 2003;14:573–582. [PubMed]

51. Tzavara ET, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 2003;138:544–553. [PMC free article] [PubMed]

52. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by delta (9)-tetrahydrocannabinol. Psychopharmacology (Berl.). 2002;163:111–117. [PubMed]

53. Genn RE, Tucci S, Marco E, Viveros MP, File SE. Anxiolytic and anxiogenic effects of the cannabinoid agonist CP 55,940 in animal tests of anxiety. J. Psychopharmacol. 2003;17:A27.

54. Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev. Biol. 1996;175:1–13. [PubMed]

55. Gritti A, et al. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. J. Neurosci. 1996;16:1091–1100. [PubMed]

56. Persson AI, Thorlin T, Bull C, Eriksson PS. Opioid-induced proliferation through the MAPK pathway in cultures of adult hippocampal progenitors. Mol. Cell. Neurosci. 2003;23:360–372. [PubMed]

57. Harada J, Foley M, Moskowitz MA, Waeber C. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J. Neurochem. 2004;88:1026–1039. [PubMed]

58. Kanemura Y, et al. Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity. J. Neurosci. Res. 2002;69:869–879. [PubMed]

59. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000;20:9104–9110. [PubMed]

60. Nixon K, Crews FT. Temporally specific burst in cell proliferation increases hippocampal neurogenesis in protracted abstinence from alcohol. J. Neurosci. 2004;24:9714–9722. [PubMed]

61. Crews FT, Nixon K, Wilkie ME. Exercise reverses ethanol inhibition of neural stem cell proliferation. Alcohol. 2004;33:63–71. [PubMed]

62. West MJ. New stereological methods for counting neurons. Neurobiol. Aging. 1993;14:275–285. [PubMed]

63. Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl.). 1988;95:298–302. [PubMed]